Notably, some studies demonstrated that HDAC inhibitors treatment represented an effective strategy to target LSCs in CP-CML patients receiving tyrosine kinase inhibitors [34, 35]. Here, HDAC9 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.